During the 26- to 78-week treatment periods in 5 clinical trials in adults with type 2 diabetes mellitus [see Clinical Studies (14.2, 14.3)] and 1 clinical trial in Japanese adults with type 2 diabetes mellitus, 14/2,924 (0.5%) of semaglutide tablet-treated patients developed anti-semaglutide antibodies
Dose adjustments : If gastrointestinal side effects are problematic, the Wegovy SmPC advises considering slower dose escalation or temporary dose reduction
Frequently, there are several tumors
If you want to understand how people often evaluate this kind of treatment path, our GLP-1 intake quiz can help you see what options may fit
In the EU it can be labeled yeast protein
pharmaceutical-grade DSIP Because it isnt FDA-approved, most commercially available DSIP is research-grade material